Maraviroc as GVHD Prophylaxis in Transplant Recipients

Phase 1/2 Terminated 31 enrolled Children's Hospital Medical Center, Cincinnati

NaSingle-groupOpen-labelPrevention

Summary

The purpose is to determine if the addition of Maraviroc to a standard transplant regimen will reduce the incidence of graft versus host disease in children and young adults after a stem cell transplant.

Timeline

Start: 2014-07
Primary completion: 2018-09
Completion: 2018-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Maraviroc	Other / unclassified	100 mg	Oral
Subject	Maraviroc	Other / unclassified	300 mg	Oral

Maraviroc as GVHD Prophylaxis in Transplant Recipients

Summary

Timeline

Drugs

Indications